Ignite Creation Date:
2024-05-05 @ 7:01 PM
Last Modification Date:
2024-10-26 @ 9:39 AM
Study NCT ID:
NCT00580970
Status:
COMPLETED
Last Update Posted:
2016-11-18
First Post:
2007-12-20
Brief Title:
Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury
Sponsor:
Virginia Commonwealth University
Organization:
Virginia Commonwealth University
Study Overview
Official Title:
A Phase II Study to Prevent Radiation-Induced Rectal Injury With Lovastatin
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Lovastatin may protect against late effects of radiation therapy in patients with prostate cancer
Detailed Description:
Oral lovastatin will be given at the dose of 20 mgday with evening meal beginning on the first day of external beam radiation therapy external beam alone or external beam followed by brachytherapy or on the first day of brachytherapy brachytherapy alone or brachytherapy followed by external beam radiotherapy and continue for 12 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-2011-01676 | REGISTRY | CTRP Clinical Trial Reporting Program | None |